First FDA Approval and Demonstrated Efficacy

Celcuity's pan-PI3K/mTOR inhibitor, Revtorpyk (generic name: gedatolisib), has received marketing authorization from the U.S. Food and Drug Administration (FDA). This approval is based on the Phase 3 VIKTORIA-1 study, targeting patients with hormone receptor-positive (HR+), HER2-negative, and PIK3CA wild-type advanced breast cancer. In the clinical trial, the Revtorpyk triple combination therapy demonstrated remarkable efficacy, reducing the risk of disease progression and death by 76% (HR 0.24) compared to fulvestrant monotherapy. This is considered a highly encouraging clinical result, especially for patients who have developed resistance to existing treatments.

Delayed Launch Triggers Disappointment

Despite the impressive efficacy data and rapid approval, Celcuity's stock price experienced a paradoxical drop of approximately 20% immediately after the announcement. This was because the company projected the commercial launch of Revtorpyk for the end of the third quarter of 2026, which was later than investors had anticipated. The market expected the company to be in a state of launch readiness, but the actual supply schedule being delayed raised concerns about short-term cash flow. This serves as a prime example of how new drug approval does not immediately guarantee revenue growth, highlighting the realities of the commercialization phase.

Safety Uncertainties Revealed in Prescribing Label

Another major factor contributing to the stock decline was the adverse event data included in the FDA prescribing information. The prescribing label indicated that the permanent discontinuation rate for the Revtorpyk triple combination therapy due to adverse events was 12%, and the dose interruption rate was as high as 64%. This is significantly higher than the treatment-related adverse event (TRAE) discontinuation rate of 2.3% that Celcuity had previously presented at conferences, surprising analysts. Although the label data includes all adverse events, regardless of whether they are treatment-related, it could negatively impact prescribing behavior in clinical practice.

Pioneering a Differentiated Market and Remaining Challenges

Nevertheless, Revtorpyk has secured the opportunity to establish a dominant position by targeting the PIK3CA wild-type market, which accounts for approximately 60% of all HR+/HER2- patients. Unlike existing competitor drugs, which are primarily developed for PIK3CA-mutated patients, Revtorpyk offers a new standard of care for the large unmet need in the wild-type patient population. The company plans to file a supplemental New Drug Application (sNDA) in the third quarter of this year to expand the indication to PIK3CA-mutated patients. In the future, the actual prescribing patterns of physicians and the establishment of patient protocols for managing adverse events will be key determinants of the drug's commercial success.